About
Vasculonics is a preclinical stage biotechnology company focused on developing new class of disease modifying medicine for pulmonary artery hypertension (PAH) and chronic kidney disease (CKD).
We are focused on developing pharmacological approaches to reduce disease progression and mortality in PAH and CKD.
Company Timeline
2017- Founded
2019- SBIR Phase I Award
A Novel Therapeutic DDAH for the Treatment of Acute Kidney Injury
2020- SBIR Phase I Award
Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension
2020- NHILB Catalyze Award
Synthesis New Compounds and Lead Optimization of Small Molecule DDAH-1 Modulator
2021- BARDA Blue Knight QuickFire Winner
2024- SBIR Phase II Award
Development of a Novel Disease Modifying Oral Therapy for Pulmonary Arterial Hypertension
> $4 million grants awarded
Science and Technology
Selective Aryl Hydrocarbon Receptor Modulators (SAhRM)
AhR is known to play important pathological roles in inflammatory and fibrotic diseases [1,2]. AhR activation has been found essential for PAH progression in humans and animal models [3].
Vasculonics is developing novel selective aryl hydrocarbon receptor modulators (SAhRM) and suppressor of vascular toxin asymmetric dimethyl arginine (ADMA) the critical pathological mechanisms of PAH.
VN-1032 is a novel SAhRM with major impact on the mechanisms of inflammation, oxidative stress and fibrosis.
VN-1032 has demonstrated disease modifying efficacy in a PAH and CKD disease progression models when delivered as an oral formulation.
1. Beischlag TV., et al. Crit. Rev. Eukaryot. Gene Expr. 2008, 18 (3), 207–250.
2. Perdew GH., et al. Int. J. Mol. Sci. 2023, 24 (6).
3. Masaki T., et al. Proc. Natl. Acad. Sci. U. S. A. 2021, 118 (11), e2023899118.
VN-1032 reduced (A) kidney, (B) cardiac fibrosis in rat model of CKD.
VN-1032 reduced (A) remodeling of lung vessels, (B) reduced lung inflammation in Sugen-Hypoxia PAH model.
Therapeutic Extracorporeal Device (TED)
Vasculonics has developed an extracorporeal device to selectively lower pathological ADMA from blood and demonstrate organ protection in preclinical models of kidney and heart damage [1]. Potential therapeutic applications of the extracorporeal device include the treatment of sepsis, acute kidney injury, and hepatic renal syndrome [2].
1. Lee Y., et al. Blood Purif. 2022, 51 (11), 889–898.
2. Singh J., et al. Critical Care. 2022, 26(1), 246.
Team Members
Jaipal Singh, PhD
CSO & Founder
Jon Northrup
CEO
Michael Coleman, PhD
CBO
Srinivas Kasibhatla, PhD
Chemistry Advisor
Young Lee, PhD
Program Leader
Advisory Board
Robert Bacallao, MD
Chief Medical Advisor
Vijay Reddy, PhD, DABT
SVP, Toxicology
Anantha Shekhar, MD, PhD
Co-Founder, SAB
John A Kellum, MD
SAB